-
2025 CASH丨Dr. Yongrong Lai: Advances in Gene Therapy for Thalassemia
Thalassemia, an inherited blood disorder, imposes a significant economic and resource burden on patients, families, and society at large. In recent years, advances in medical research have led to a growing range of treatment options for thalassemia, including traditional blood transfusions and iron chelation therapy, drugs to induce gamma-globin production, hematopoietic stem cell transplantation (HSCT),…
-
ASH 2024 | Dr. Neha Mehta-Shah Discusses Challenges and Innovations in T-Cell Lymphoma Treatment
Significant progress has been made in the treatment of T-cell lymphomas in recent years. However, challenges persist in managing relapsed/refractory disease, selecting optimal therapies, and determining the best treatment sequencing for patients. To address these issues, the 2024 American Society of Hematology (ASH) Annual Meeting featured an educational session titled Addressing Unmet Needs in T-Cell…
-
Annual Review | Dr. Dingwei Ye: Key Advances in Systemic Therapy for Advanced Prostate Cancer
Prostate cancer is one of the most common malignancies affecting the male genitourinary system, and in China, a significant proportion of newly diagnosed patients present with advanced disease. Since late-stage prostate cancer is symptomatic and not curable, alleviating symptoms, delaying disease progression, and improving quality of life have always been priorities for both patients and…
-
Emerging CAR-T Therapies: A Breakthrough in Treating Gastrointestinal Cancers
CAR-T Therapy in GI Cancers Adoptive T-cell therapies, including CAR-T, TCR-T, and tumor-infiltrating lymphocyte (TIL) therapies, are being explored for their potential to improve outcomes in GI cancers. CAR-T therapy,…
-
Emerging Therapies in Gastrointestinal Cancers: Advances in Bispecific Antibodies and Antibody-Drug Conjugates
Antibody-Drug Conjugates in GI Cancers ADCs are designed to enhance the precision of chemotherapy by selectively delivering cytotoxic payloads to tumor cells while minimizing systemic toxicity. The presentation emphasized key…
-
Annual Review | Dr. Kan Gong: Advances in the Diagnosis and Treatment of Localized Prostate Cancer in 2024
Prostate cancer is one of the most common malignancies threatening men’s health worldwide. With population aging and lifestyle changes, the incidence of prostate cancer in China has been steadily increasing in recent years. As an early-stage disease, localized prostate cancer generally has a favorable prognosis, with curative potential through comprehensive treatment primarily centered on local…
-
Annual Review | Dr. Qiang Liu: Advances in Systemic Therapy for Triple-Negative Breast Cancer in 2024
Breast cancer has become one of the most common malignancies among women, with triple-negative breast cancer (TNBC) being considered the most aggressive subtype due to its historically poor prognosis. Looking back at 2024, significant research breakthroughs have emerged in both early-stage and advanced TNBC treatment, covering chemotherapy, targeted therapy, immunotherapy, and antibody-drug conjugates (ADCs). Many…
-
Annual Review | Addressing Unmet Needs: Dr. Qiang Wei on Advances in Bladder Cancer Treatment in 2024
Bladder cancer is one of the most common malignancies of the urinary system, posing a serious threat to public health in China. For patients with localized disease, repeated intravesical treatments and follow-up procedures require frequent hospital visits, while those who undergo surgery often face the lifelong challenge of urinary diversion. Patients with inoperable advanced bladder…
Connecting Medical Expertise through Media